SCHEMBL20604103

SCHEMBL20604103

Cc1ccc(C)c(-n2nc(C)c(C(=O)O)c2C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
WNT3A P56704 2/20 0.56
POLB P06746 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
EGLN1 Q9GZT9 1/20 0.44
OPRM1 P35372 1/20 0.44
MAPT P10636 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
ALKBH1 Q13686 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604097 0.82 PDE4B (0.62) WNT3AKDM4EMAPTRAB9ANPC1
SCHEMBL16857585 0.77 LMNA (0.56) LMNAWNT3APOLBTDP1L3MBTL1
SCHEMBL31673548 0.74 LMNA (0.59) LMNAWNT3APOLBL3MBTL1EGLN1
SCHEMBL20604207 0.73 WNT3A (1.00) WNT3AMAPTRAB9ANPC1TP53
SCHEMBL20604195 0.73 WNT3A (0.58) LMNAWNT3APOLBTDP1L3MBTL1
SCHEMBL2319910 0.73 ALDH1A1 (0.50) LMNAWNT3AKDM4EOPRM1MAPT
SCHEMBL21068095 0.73 LMNA (0.70) LMNAWNT3APOLBL3MBTL1KDM4E
SCHEMBL20604104 0.73 RAB9A (0.51) KDM4ERAB9ANPC1
SCHEMBL15180443 0.73 ALKBH1 (0.48) LMNAPOLBTDP1L3MBTL1KDM4E
SCHEMBL2938583 0.72 MEN1 (0.69) WNT3APOLBTDP1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV OF MARYLAND BALTIMORE (US) 2026-05-21 US disclosed
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-08-05 US disclosed
EP-3423452-B1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV MARYLAND (US) 2025-05-07 EP disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 US disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-01-05 US disclosed
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-01-05 US disclosed
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2020-09-24 US disclosed
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2020-09-24 US disclosed
US-10723715-B2 2020-07-28 US disclosed
US-10723715-B2 2020-07-28 US disclosed
US-20190071424-A1 WNT Signaling Pathway Inhibitors for Treatments of Disease UNIVERSITY OF MARYLAND, BALTIMORE 2019-03-07 US disclosed
US-20190071424-A1 WNT Signaling Pathway Inhibitors for Treatments of Disease UNIVERSITY OF MARYLAND, BALTIMORE 2019-03-07 US disclosed
EP-3423452-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE University of Maryland, Baltimore (US) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-20190071424-A1 WNT Signaling Pathway Inhibitors for Treatments of Disease WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE CTNNB1, WNT1, CTNND1 LMNA 1227/4885WNT3A 5/4885POLB 3943/4885
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A LMNA 1656/4885WNT3A 3/4885POLB 1211/4885
US-10723715-B2 CTNNB1, WNT1, CTNNBL1 LMNA 920/4885WNT3A 4/4885POLB 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.